Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Walgreen Shares Decline After Sales Trail Estimate

Updated on

Sept. 6 (Bloomberg) -- Walgreen Co. fell the most in more than a month after posting fiscal fourth-quarter revenue that trailed analysts’ estimates as the lack of Express Scripts Inc. customers hurt pharmacy sales.

The shares slid 1.9 percent to $35.20 at the close in New York, the biggest decline since July 23. Deerfield, Illinois-based Walgreen, the largest U.S. drugstore chain, has gained 6.5 percent this year.

Sales in the three months ended Aug. 31 fell about 4.9 percent to $17.1 billion, Walgreen said today in a statement. That trailed the $17.2 billion average of 17 analysts’ estimates compiled by Bloomberg.

Walgreen has lost customers this year to CVS Caremark Corp. and Wal-Mart Stores Inc. after its agreement to provide prescriptions for Express Scripts customers expired. Walgreen and Express Scripts renewed that contract in July, and the drugstore chain will become part of the benefits provider’s network again on Sept. 15.

Not being part of Express Scripts’ network reduced comparable-store prescription sales by 10.7 percentage points in August, Walgreen said. Total August pharmacy sales slid 7.2 percent, the company said.

Adding to Walgreen’s slump today is a decision by Tricare, the health plan for military personnel and their dependents, to continue excluding the company from its network of retail pharmacies, said John Heinbockel, an analyst at Guggenheim Securities LLC in New York. The retailer left the Tricare network Dec. 31 when its contract with Express Scripts ended.

“We had assumed that Walgreen would be in this plan and that it would recover 50 percent of the lost business,” Heinbockel wrote today in a note. He rates Walgreen a buy.

To contact the reporter on this story: Chris Burritt in Greensboro at cburritt@bloomberg.net

To contact the editor responsible for this story: Robin Ajello at rajello@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.